查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1190734

空膠囊市場——增長、趨勢、COVID-19 的影響和預測 (2023-2028)

Empty Capsules Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，空心膠囊市場預計將以 7.4% 的複合年增長率增長。

預計 COVID-19 大流行將對市場增長產生積極影響。 由於增強免疫力的發展在對抗病毒感染方面發揮著重要作用，因此對天然草藥和膳食補充劑形式的免疫增強劑的需求不斷增長。 除基本衛生外，適當的飲食和生活方式對於預防和治療 COVID-19 等呼吸道病毒性疾病至關重要。 根據 2020 年發表的一篇研究論文，所有 COVID-19 患者都應在入院時接受營養不良篩查並評估血清維生素 D 水平。 此外，2020 年 3 月，Stabiltech BioPharma Ltd 開發了一種用於注射 COVID-19 疫苗的新型口服膠囊。 因此，預計 COVID-19 大流行將增加對膳食補充劑的需求並促進市場增長。

推動市場增長的關鍵因素包括膠囊比其他給藥形式越來越受歡迎，以及空膠囊供應商和明膠製造商之間的戰略合作夥伴關係不斷加強。 此外，世界人口老齡化加劇，增加了對各種治療藥物和營養補充劑的需求，以實現更好的健康。 根據聯合國世界老齡化人口：2020 年修訂版，到 2050 年將有約 15 億人超過 65 歲，高於 2020 年的 7.27 億。 此外，膠囊輸送技術的快速進步有望補充市場增長。 然而，道德問題、明膠材料的價格波動以及製藥行業的嚴格法規預計將阻礙市場增長。

主要市場趨勢

心血管治療領域有望在預測期內實現健康的複合年增長率

心血管疾病 (CVD) 在世界範圍內高發。 根據世界衛生組織 2019 年的數據，全球每年估計有 1790 萬人死於心血管疾病，預計到 2030 年這一數字將增加到 2360 萬以上。 此外，根據美國心臟協會 2020 年調查報告，心血管疾病被列為根本死因，每天在美國造成約 2,353 人死亡，平均每 37 秒就有 1 人死亡。 根據英國心臟基金會中心的數據，到 2021 年，英國約有 760 萬人患有心臟和循環系統疾病。 在英國，每年有超過 40,000 名 75 歲以下的人死於心臟和循環系統疾病。 全球範圍內心血管疾病的流行增加了對心血管治療藥物有效治療的需求，從而促進了市場的增長。

此外，在 COVID-19 流行期間，美國心髒病學會和加拿大心髒病學會提倡心臟干預，例如通過運動訓練和飲食諮詢進行家庭心臟康復、藥物管理、戒菸諮詢和社會心理評估干預。公佈了重新引入服務的指南。 因此，預計心臟康復課程的增加將在 COVID-19 流行期間推動研究領域的發展。

2019 年 9 月，Lupin 還獲得了加拿大衛生監管機構的批准，用於治療高血壓和減輕心絞痛的鹽酸普□洛爾緩釋膠囊。 預計增加產品批准也將在預測期內推動這一細分市場。

空膠囊可有效掩蓋心臟藥物的味道並防止患者感到噁心。 因此，隨著 CVD 患病率的上升，對心臟藥物的需求也會增加。 這一因素可能會對空心膠囊市場產生積極影響。

北美佔據了很大的市場份額，預計在預測期內將繼續保持這一勢頭

由於人們越來越偏愛基於膠囊的膳食補充劑配方，該地區佔據了主要份額。 這些膳食補充劑的消費量正在增加，因為它們有助於預防肥胖、癌症和關節炎等重大健康問題。 此外，該地區營養補充劑行業對空膠囊的需求很高，因為膠囊是最受歡迎的固體口服劑型。

此外，隨著美國人口老齡化，慢性病負擔的加重也被認為是北美市場增長的主要因素。 根據人口事務研究所的美國人口公報 - 老齡化，預計到 2060 年，65 歲及以上的美國人數量將從 2018 年的 5200 萬增加近一倍至 9500 萬。 同樣，2019 年 CRN 膳食補充劑消費者調查的一份報告發現，77% 的美國人表示他們服用膳食補充劑。 調查還發現，維生素和礦物質是 2019 年美國人最常食用的補充劑，佔所有膳食補充劑的 76%，其次是專業補充劑 (40%)、草藥和植物 (39%)、運動營養補充劑 (28 %) 和體重管理補充劑 (17%)。

但是，在 COVID-19 大流行期間，大多數肉類加工設施都關閉了，限制了明膠的供應。 此外，由於國際邊界的運輸限制，預計北美將對明膠膠囊的供應鏈產生嚴重影響，阻礙該地區的市場增長。

此外，美國和加拿大還開發和構建了鼓勵研究和開發的醫療保健系統。 它還鼓勵全球公司進入美國和加拿大。 因此，這些國家將有許多世界球員。 由於全球公司在該地區的存在滿足了高需求，預計該市場將在預測期內進一步增長。

競爭格局

大部分空心膠囊由世界領先的公司生產。 擁有更多研究資金和更好的分銷系統的市場領導者正在市場中站穩腳跟。 空心膠囊市場高度整合，由 ACG Worldwide、Medi-Caps Ltd、LonzaGroup (Capsugel)、Capscanada Corporation、Bright Pharma Caps Inc 等幾家主要參與者組成。 由於空心膠囊意識的增強，亞太地區也出現了一些中小型玩家。 此外，主要參與者正在參與戰略聯盟和產品發布，以確保他們在競爭市場中的地位。 例如，2020 年 10 月，龍沙 (Lonza) 向其膠囊和保健成分 (CHI) 部門投資 8500 萬瑞士法郎，以將其膠囊製造能力擴大到每年 300 億粒膠囊。

其他福利。

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 增加製藥應用
    • 空心膠囊技術進展
    • 老年人口增加
  • 市場製約因素
    • 明膠價格上漲，原材料獲取困難
    • 文化習俗和飲食限制
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模：百萬美元）

  • 按產品分類
    • 明膠膠囊
    • 非明膠膠囊
  • 職能性別
    • 速釋膠囊
    • 緩釋膠囊
    • 緩釋膠囊
  • 通過使用
    • 抗生素和抗菌劑
    • 維生素和營養補充劑
    • 抗酸藥和抗脹氣藥
    • 心血管藥物
    • 其他治療用途
  • 最終用戶
    • 醫藥行業
    • 營養保健品
    • 化妝品行業
    • 研究所
  • 區域信息
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東和非洲地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • ACG Worldwide
    • Bright Pharma Caps Inc.
    • Capscanada Corporation
    • Lonza Group（Capsugel）
    • Medi-Caps Ltd
    • Qualicaps
    • Suheung Capsule Co. Ltd
    • Qingdao Yiqing Medicinal Capsules Co. Ltd
    • Shanxi Guangsheng Medicinal Capsules Co. Ltd
    • Healthcaps India Ltd
    • Nectar Lifesciences Ltd
    • Shanxi JC Biological Technology Co. Ltd

第7章 市場機會今後動向

簡介目錄
Product Code: 64988

The empty capsules market is expected to record a CAGR of 7.4% over the forecast period.

The COVID-19 pandemic is expected to positively impact the market's growth. As the development of strong immunity plays a vital role in fighting against viral infection, there has been an increasing demand for immunity boosters in the form of natural herbs and nutraceuticals. Apart from the basic hygienic practices, proper dietary and lifestyle behaviors are essential for preventing and treating respiratory viral diseases, such as COVID-19. As per the research article published in 2020, every COVID-19 patient should be screened for malnutrition on admission and assessed for serum vitamin D levels. Additionally, in March 2020, Stabilitech BioPharma Ltd developed a new oral capsule to deliver the COVID-19 vaccine. Thus, the COVID-19 pandemic is boosting the demand for nutraceuticals, which is expected to help the market to grow.

The key factors that boost the market's growth include a rise in the popularity of capsules over other drug delivery forms and an increase in strategic collaborations between empty capsule suppliers and gelatin manufacturers. Also, the growing geriatric population worldwide increases the demand for various therapy drugs and dietary supplements for better health outcomes. According to the United Nations, World Ageing Population: the 2020 Revision, by 2050, approximately 1.5 billion people are likely to be over 65 years, up from 727 million in 2020. In addition, rapid advancements in capsule delivery technologies are set to supplement the market's growth. However, ethical concerns, price fluctuations regarding gelatin materials, and stringent regulations in the pharmaceutical industry are expected to hamper the market growth.

Key Market Trends

The Cardiovascular Therapy Drugs Segment is Expected to Witness a Healthy CAGR Over the Forecast Period

Cardiovascular diseases (CVD) are highly prevalent globally. According to the World Health Organization 2019, an estimated 17.9 million people die due to cardiovascular diseases worldwide each year, and the number is expected to grow to more than 23.6 million by 2030. Additionally, as per the American Heart Association Research Report 2020, cardiovascular disease, listed as the underlying cause of death, accounts for nearly 2,353 deaths daily in United States, which is an average of 1 death every 37 seconds. Also, according to the British Heart Foundation Centre, 2021, around 7.6 million people were living with heart and circulatory diseases in United Kingdom. More than 40,000 people under the age of 75 years in United Kingdom die from heart and circulatory diseases each year. The high incidence of cardiovascular diseases worldwide surges the demand for cardiovascular therapy drugs for effective treatment, thus driving the market's growth.

Additionally, during the COVID-19 pandemic, the American College of Cardiology and the Canadian Cardiovascular Society issued guidelines for the reintroduction of cardiac services, including home-based cardiac rehabilitation that provide exercise training and dietary counseling, medication management, tobacco cessation counseling, and psychosocial assessment interventions. Hence, the increasing cardiac rehabilitation sessions are expected to boost the studied segment during the COVID-19 pandemic.

Also, in September 2019, Lupin received approval from the Canadian health regulator for its Propranolol Hydrochloride extended-release capsules used to treat hypertension and decreased frequency of angina. The increasing product approvals are also expected to boost the segment over the forecast period.

Empty capsules are useful in masking the taste of cardiac therapy drugs, which prevents the patient from feeling nauseated. Hence, as the prevalence of CVDs increases, the demand for cardiac therapy drugs will also increase. This factor may positively impact the empty capsules market.

North America Holds a Significant Share in the Market and is Expected to Continue the Trend over the Forecast Period

The region holds a major share due to the rising preference for capsule-based nutraceutical formulations. Since these nutraceuticals help prevent major health problems, such as obesity, cancer, and arthritis, their consumption has increased. Additionally, capsules are the most preferred solid oral dosage forms, and thus, the demand for empty capsules in the nutraceutical industry is high in the region.

Also, the growing burden of chronic diseases, along with the rising geriatric population in United States, is considered a major factor for the growth of the market in North America. According to the Population Reference Bureau's Population Bulletin-Aging in United States, the number of Americans aged 65 years and older is projected to nearly double from 52 million in 2018 to 95 million by 2060. Similarly, as per the CRN Consumer Survey on Dietary Supplements, 2019 report, 77% of Americans reported consuming dietary supplements. Also, the survey revealed that vitamins and minerals were the most common supplements consumed by the American population in 2019, accounting for 76% of total dietary supplement consumption, followed by specialty supplements (40%), herbals and botanicals (39%), sports nutrition supplements (28%), and weight management supplements (17 %) in 2019.

However, during the COVID-19 pandemic, most meat processing facilities were shut down, which limited the availability of gelatin. Additionally, due to the transport restrictions in the borders of various countries worldwide, North America is expected to be severely impacted on the supply chain of the gelatin capsule, which is expected to hamper the market's growth in the region.

Moreover, United States and Canada have a developed and well-structured healthcare system, which encourages research and development. They also encourage global players to enter United States and Canada. As a result, these countries enjoy the presence of many global market players. As the high demand is met by the presence of global players in the region, the market is further expected to grow over the forecast period.

Competitive Landscape

Global key players are manufacturing the majority of empty capsules. Market leaders with more funds for research and a better distribution system have established their positions in the market. The empty capsules market is highly consolidated and consists of a few major players, including ACG Worldwide, Medi-Caps Ltd, LonzaGroup (Capsugel), Capscanada Corporation, and Bright Pharma Caps Inc. Moreover, Asia-Pacific is witnessing the emergence of a few small- and medium-sized players due to the rising awareness of empty capsules. Additionally, key players are involved in strategic alliances and product launches to secure their positions in the competitive market. For instance, in October 2020, Lonza invested CHF 85 million in its Capsules and Health Ingredients (CHI) division to expand its capsule manufacturing capacity by 30 billion capsules annually.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Pharmaceutical Applications
    • 4.2.2 Technological Advancements in Empty Capsules
    • 4.2.3 Growing Geriatric Population
  • 4.3 Market Restraints
    • 4.3.1 Rising Gelatin Prices and Lower Availability of Raw Materials
    • 4.3.2 Cultural Practices and Dietary Restrictions
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product
    • 5.1.1 Gelatin Capsules
    • 5.1.2 Non-gelatin Capsules
  • 5.2 By Functionality
    • 5.2.1 Immediate-release Capsules
    • 5.2.2 Delayed-release Capsules
    • 5.2.3 Sustained-release Capsules
  • 5.3 By Therapeutic Application
    • 5.3.1 Antibiotic and Antibacterial Drugs
    • 5.3.2 Vitamins and Dietary Supplements
    • 5.3.3 Antacid and Antiflatulent Preparations
    • 5.3.4 Cardiovascular Therapy Drugs
    • 5.3.5 Other Therapeutic Applications
  • 5.4 By End User
    • 5.4.1 Pharmaceutical Industry
    • 5.4.2 Nutraceutical Industry
    • 5.4.3 Cosmetics Industry
    • 5.4.4 Research Laboratories
  • 5.5 By Geography
    • 5.5.1 North America
      • 5.5.1.1 United States
      • 5.5.1.2 Canada
      • 5.5.1.3 Mexico
    • 5.5.2 Europe
      • 5.5.2.1 Germany
      • 5.5.2.2 United Kingdom
      • 5.5.2.3 France
      • 5.5.2.4 Italy
      • 5.5.2.5 Spain
      • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
      • 5.5.3.1 China
      • 5.5.3.2 Japan
      • 5.5.3.3 India
      • 5.5.3.4 Australia
      • 5.5.3.5 South Korea
      • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle-East and Africa
      • 5.5.4.1 GCC
      • 5.5.4.2 South Africa
      • 5.5.4.3 Rest of Middle-East and Africa
    • 5.5.5 South America
      • 5.5.5.1 Brazil
      • 5.5.5.2 Argentina
      • 5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 ACG Worldwide
    • 6.1.2 Bright Pharma Caps Inc.
    • 6.1.3 Capscanada Corporation
    • 6.1.4 Lonza Group (Capsugel)
    • 6.1.5 Medi-Caps Ltd
    • 6.1.6 Qualicaps
    • 6.1.7 Suheung Capsule Co. Ltd
    • 6.1.8 Qingdao Yiqing Medicinal Capsules Co. Ltd
    • 6.1.9 Shanxi Guangsheng Medicinal Capsules Co. Ltd
    • 6.1.10 Healthcaps India Ltd
    • 6.1.11 Nectar Lifesciences Ltd
    • 6.1.12 Shanxi JC Biological Technology Co. Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS